CD Biosynsis offers specialized HeLa Cells Gene Knockout Services, providing permanent and precise deletion or disruption of target genes in this foundational human cell line. Gene knockout in HeLa cells is a critical tool for functional genomic studies, identifying essential genes for cellular pathways, and creating disease models (e.g., studying cancer cell viability or viral infection mechanisms). Leveraging the precision of CRISPR-Cas9 to induce double-strand breaks (DSBs), our services rely on the cell's Non-Homologous End Joining (NHEJ) pathway to generate stable, multi-allelic, loss-of-function mutations (indels). We provide end-to-end solutions, from gRNA design validated for the complex HeLa genome to final clone screening, accelerating the validation of novel therapeutic targets and the dissection of complex cellular processes.
Get a QuoteHeLa cells are characterized by aneuploidy (abnormal chromosome number), often having three or more copies of many genes. Achieving a definitive functional knockout requires highly efficient disruption across multiple alleles. Our CRISPR-Cas9 platform is optimized to address this by focusing on high-efficiency, multi-allelic disruption. Cas9 induces a double-strand break (DSB) at the target locus, which the cell repairs via the error-prone Non-Homologous End Joining (NHEJ) pathway. This repair often results in frameshift mutations (insertions or deletions, or indels) that functionally disrupt the gene. This robust strategy is critical for creating stable, genetically clean KO cell lines essential for reproducible research, such as removing host factors required for viral entry or signaling molecules in cancer pathways.
Multi-Allelic KO Design
Design of gRNA(s) targeting the early coding sequence to maximize the chance of frame-shift mutations (indels) that disrupt the functional protein product across all alleles (critical for the HeLa genome).
Multiplex Knockout
Utilization of highly active Cas9 and multiplex gRNA arrays to simultaneously disrupt multiple target genes, accelerating the study of redundant pathways or large functional complexes.
Indel Verification Primers
Design of robust PCR and sequencing primers spanning the gRNA cut site for definitive, clone-level verification of successful indel formation using TIDE analysis or deep sequencing.
RNP Delivery System
Preference for Ribonucleoprotein (RNP) complexes (Cas9 protein + gRNA) for transient, high-efficiency, and low off-target delivery into HeLa cells via optimized electroporation/lipofection.
Lentivirus/Plasmid Delivery
Used for stable editing of Cas9 or gRNA cassettes in applications requiring sustained editing pressure or for creating inducible KO systems.
Reporter-Assisted Selection
Use of co-transfected fluorescent reporters (e.g., GFP) or drug selection markers to enrich for the high-editing cell population, streamlining clonal isolation.
Viral Pathogen Studies
Disruption of host cell receptors or accessory factors critical for viral entry (e.g., SARS-CoV-2, HPV) or replication pathways.
Cancer Signaling Dissection
Knockout of oncogenes (e.g., $\text{RAS}$) or key components of proliferative/anti-apoptotic signaling cascades to study drug sensitivity and cancer cell fitness.
Cell Cycle/Apoptosis Analysis
Targeted disruption of regulators (e.g., $\text{CDK}$, $\text{p}53$, $\text{Bax}$) to analyze their definitive roles in cellular progression and programmed cell death.
A systematic process for achieving precise disruption and stable clone isolation.
1. Rational Design & RNP Preparation
2. Transfection & Selection
3. Single Cell Cloning & Screening
4. Clone Verification & Delivery
Identify target gene(s) and all relevant alleles. Design and synthesize high-specificity gRNA(s) targeting the early coding region, optimized for high multi-allelic disruption.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex for transient, high-titer delivery.
Design primers for verification of indel formation (TIDE/Sanger/Deep Sequencing) at the target locus.
Deliver the RNP complex (and selection marker) into the HeLa host cell line via optimized protocols.
Culture cells to allow the NHEJ repair pathway to finalize the genomic edit.
Apply antibiotic selection or FACS sorting to enrich for edited clones.
Genotype verification via sequencing of the edited locus(i) to confirm multi-allelic indel formation.
Phenotypic validation of the final clone's functional stability (e.g., loss of protein expression, altered pathway activity) over multiple passages.
Delivery of the verified Master Cell Bank (MCB) or research cell line and complete documentation.
Aneuploidy Management
Dedicated expertise and screening protocols (Deep Sequencing, Functional Screening) ensure definitive loss-of-function across all alleles in the hyper-triploid HeLa genome.
High Efficiency Delivery
Leveraging the high transfectability of HeLa cells with RNP complexes maximizes the simultaneous editing rate needed for multi-allelic disruption.
Stable Functional Model
Guaranteed monoclonal isolation and genomic verification yields highly reproducible KO cell lines, critical for long-term cell biology and drug screening studies.
Accelerated Target Validation
Rapid creation of KO models for viral host factors or cancer signaling components allows for quicker in vitro validation of potential therapeutic targets.
1. Why is multi-allelic knockout necessary in HeLa cells?
HeLa cells are highly aneuploid (abnormal chromosome number), meaning many genes have multiple functional alleles (often three or more). To ensure a complete loss-of-function, all alleles must be disrupted simultaneously.
2. How do you verify complete functional knockout across all alleles?
Verification is done through both genotyping (Deep Sequencing to confirm disruptive indels on all alleles) and phenotypic analysis (e.g., Western Blot to confirm the complete absence of the target protein, or functional assays to confirm pathway loss).
3. What is the preferred delivery system for CRISPR in HeLa cells?
The RNP (Ribonucleoprotein) complex delivered via optimized electroporation or lipofection is preferred. HeLa cells transfect easily, and RNP provides transient, high-efficiency editing, minimizing off-target effects and toxicity.
4. Can you perform knockout of essential genes?
Knockout of truly essential genes is usually lethal. For these targets, we recommend using tunable repression systems like CRISPRi (CRISPR Interference) to study their functional contribution without causing cell death.
5. How does the knockout process help in viral research?
It allows for the creation of isogenic HeLa lines deficient in specific host factors (e.g., $\text{AP}2\text{M}1$) required for viral internalization or replication. This is crucial for definitively studying the viral lifecycle and screening antiviral drugs.
6. What input is required to start a HeLa KO project?
We require the specific target gene sequence (accession number or sequence) and confirmation of the desired functional outcome (e.g., complete loss of protein function).
7. What is included in the final clone delivery?
The final delivery includes the cryopreserved, verified clonal HeLa cell line, the editing strategy and sequence data (TIDE/Sanger/Deep Sequencing), and a Certificate of Analysis (CoA) confirming the modification and functional status.
8. What is the role of NHEJ in this service?
NHEJ (Non-Homologous End Joining) is the cell's main mechanism for repairing the Cas9-induced double-strand break. Because it is error-prone, it introduces small insertions or deletions (indels) that cause a frameshift, functionally silencing the gene.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.